MAPT and Alzheimer disease: In 2018 National Institute of Health (NIH) and Alzheimer’s Association proposed a research framework for biological definition of Alzheimer’s disease [32] as an ATN(C) classification where AD biomarkers can measure A (amyloid beta deposition), T(pathologic Tau), N (neurodegeneration), and C (clinical manifestations).